<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">80328</article-id><article-id pub-id-type="doi">10.7554/eLife.80328</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Selection of HIV-1 for resistance to fifth generation protease inhibitors reveals two independent pathways to high-level resistance</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-281752"><name><surname>Spielvogel</surname><given-names>Ean</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281753"><name><surname>Lee</surname><given-names>Sook-Kyung</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-181823"><name><surname>Zhou</surname><given-names>Shuntai</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281754"><name><surname>Lockbaum</surname><given-names>Gordon J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281755"><name><surname>Henes</surname><given-names>Mina</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281756"><name><surname>Sondgeroth</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281757"><name><surname>Kosovrasti</surname><given-names>Klajdi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281758"><name><surname>Nalivaika</surname><given-names>Ellen A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-281759"><name><surname>Ali</surname><given-names>Akbar</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269968"><name><surname>Yilmaz</surname><given-names>Nese Kurt</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-20602"><name><surname>Schiffer</surname><given-names>Celia A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2270-6613</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-82995"><name><surname>Swanstrom</surname><given-names>Ronald</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7777-0773</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Microbiology and Immunology</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Lineberger Comprehensive Cancer Center</institution>, <institution>University of North Carolina at Chapel Hill</institution>, <addr-line><named-content content-type="city">Chapel Hill</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Department of Biochemistry and Molecular Biotechnology</institution>, <institution>University of Massachusetts Medical School</institution>, <addr-line><named-content content-type="city">Worcester</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Biochemistry and Molecular Pharmacology</institution>, <institution>University of Massachusetts Medical School</institution>, <addr-line><named-content content-type="city">Worcester</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-55010"><name><surname>Pornillos</surname><given-names>Owen</given-names></name><role>Reviewing editor</role><aff><institution>University of Virginia</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>celia.schiffer@umassmed.edu</email> (CS);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>ron_swanstrom@med.unc.edu</email> (RS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>03</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e80328</elocation-id><history><date date-type="received"><day>16</day><month>05</month><year>2022</year></date><date date-type="accepted"><day>14</day><month>03</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Spielvogel et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Spielvogel et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-80328-v1.pdf"/><abstract><p>Darunavir (DRV) is exceptional among potent HIV-1 protease inhibitors (PIs) in high drug concentrations that are achived <italic>in vivo</italic>. Little is known about the <italic>de novo</italic> resistance pathway for DRV. We selected for resistance to high drug concentrations against ten PIs and their structural precursor DRV. Mutations accumulated through two pathways (anchored by protease mutations I50V or I84V). Small changes in the inhibitor P1'-equivalent position led to preferential use of one pathway over the other. Changes in the inhbitor P2'-equivalent position determined differences in potency that were retained in the resistant viruses and that impacted the selected mutations. Viral variants from the two pathways showed differential selection of compensatory mutations in Gag cleavage sites. These results reveal the high level of selective pressure that is attainable with fifth generation PIs, and how features of the inhibitor affect both the resistance pathway and the residual potency in the face of resistance.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>1P01GM109767-01A`</award-id><principal-award-recipient><name><surname>Spielvogel</surname><given-names>Ean</given-names></name><name><surname>Lee</surname><given-names>Sook-Kyung</given-names></name><name><surname>Zhou</surname><given-names>Shuntai</given-names></name><name><surname>Lockbaum</surname><given-names>Gordon J</given-names></name><name><surname>Henes</surname><given-names>Mina</given-names></name><name><surname>Sondgeroth</surname><given-names>Amy</given-names></name><name><surname>Kosovrasti</surname><given-names>Klajdi</given-names></name><name><surname>Nalivaika</surname><given-names>Ellen A</given-names></name><name><surname>Ali</surname><given-names>Akbar</given-names></name><name><surname>Yilmaz</surname><given-names>Nese Kurt</given-names></name><name><surname>Schiffer</surname><given-names>Celia A</given-names></name><name><surname>Swanstrom</surname><given-names>Ronald</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The sequencing data (Figure 2, 3, and 4) is available at NIH Sequencing Read Archive (SRA) under BioProject ID PRJNA853351.All source data files for enzymatic Ki and Km (Table 1, Figure 2 and 5) have been uploaded to the Carolina Digital Repository: Swanstrom, Ron, and Ean Spielvogel. Km and Ki Dataset for Selection of Hiv-1 for Resistance to Fifth Generation Protease Inhibitors Reveals Two Independent Pathways to High-level Resistance. 2022.All source data files for EC50 inhibition curves (Figure 2 and 6) have been uploaded to the Carolina Digital Repository: Swanstrom, Ron, and Ean Spielvogel. Ec50 Dataset for Selection of Hiv-1 for Resistance to Fifth Generation Protease Inhibitors Reveals Two Independent Pathways to High-level Resistance. 2022.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Henes M</collab><collab>Kosovrasti K</collab><collab>Nalivaika EA</collab><collab>Kurt Yilmaz N</collab><collab>Schiffer CA</collab></person-group><year iso-8601-date="2022">2022</year><source>Km and Ki Dataset for Selection of HIV-1 for Resistance to Fifth Generation Protease Inhibitors Reveals Two Independent Pathways to High-Level Resistance</source><ext-link ext-link-type="uri" xlink:href="https://cdr.lib.unc.edu/concern/data_sets/1r66j9866">https://cdr.lib.unc.edu/concern/data_sets/1r66j9866</ext-link><comment>Carolina Digital Repository</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Spielvogel E</collab><collab>Sondgeroth A</collab><collab>Swanstrom R</collab></person-group><year iso-8601-date="2022">2022</year><source>Display all details of EC50 Dataset for Selection of HIV-1 for Resistance to Fifth Generation Protease Inhibitors Reveals Two Independent Pathways to High-Level Resistance</source><ext-link ext-link-type="uri" xlink:href="https://cdr.lib.unc.edu/concern/data_sets/pk02cm738">https://cdr.lib.unc.edu/concern/data_sets/pk02cm738</ext-link><comment>Carolina Digital Repository</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Spielvogel E</collab><collab>Zhou S</collab><collab>Swanstrom R</collab></person-group><year iso-8601-date="2022">2022</year><source>Sequencing Data for: Selection of HIV-1 for Resistance to Fifth Generation Protease Inhibitors Reveals Two Independent Pathways to High-Level Resistance</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/853351">https://www.ncbi.nlm.nih.gov/bioproject/853351</ext-link><comment>NIH Sequencing Read Archive, PRJNA853351</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-80328-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>